|
FR2551758B1
(fr)
*
|
1983-08-16 |
1986-01-31 |
Anvar |
Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
|
|
US4650771A
(en)
*
|
1983-11-04 |
1987-03-17 |
Miles Laboratories, Inc. |
Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
|
|
US4595656A
(en)
*
|
1984-01-06 |
1986-06-17 |
Becton Dickinson & Company |
Coupling agents and products produced therefrom
|
|
US4654311A
(en)
*
|
1984-06-15 |
1987-03-31 |
Syntex (U.S.A.) Inc. |
Serum pretreatment for digoxin assay
|
|
US4767720A
(en)
*
|
1985-08-29 |
1988-08-30 |
Hsc Research Development Corporation |
Antidigoxin antibodies
|
|
US5013720A
(en)
*
|
1986-05-06 |
1991-05-07 |
Abbott Laboratories |
SAP-6-Val proteins and methods
|
|
FR2601141A1
(fr)
*
|
1986-07-02 |
1988-01-08 |
Centre Nat Rech Scient |
Produit de couplage a base d'haptene, utile notamment comme substance immunogene, anticorps correspondants et applications
|
|
US5034317A
(en)
*
|
1987-01-30 |
1991-07-23 |
Polaroid Corporation |
Enzyme controlled release system and organic conjugate reactant
|
|
US6326136B1
(en)
*
|
1988-04-01 |
2001-12-04 |
Digene Corporation |
Macromolecular conjugate made using unsaturated aldehydes
|
|
DE3836656A1
(de)
*
|
1988-10-27 |
1990-05-03 |
Boehringer Mannheim Gmbh |
Neue digoxigenin-derivate und ihre verwendung
|
|
CA2031109C
(en)
*
|
1990-07-27 |
1992-01-28 |
Susan J. Danielson |
Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
|
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
RU2132553C1
(ru)
*
|
1996-05-30 |
1999-06-27 |
Ивановская Елена Алексеевна |
Количественное определение дигоксина в сыворотке крови методом инверсионной вольтамперометрии
|
|
EP1000172A4
(en)
*
|
1997-02-18 |
2002-10-30 |
Oncor Inc |
DETECTION OF TARGET MOLECULES WITH THE "GREEN FLUORESCENT PROTEIN" AND VARIANTS THEREOF
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
ES2267263T3
(es)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
|
|
DE60035871T2
(de)
*
|
1999-05-19 |
2008-06-05 |
Merck Patent Gmbh |
Expression und export von interferon-alpha proteinen als fc fusionsproteine
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US6617135B1
(en)
*
|
1999-08-09 |
2003-09-09 |
Emd Lexigen Research Center Corp. |
Multiple cytokine protein complexes
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
DK1252192T3
(da)
*
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
|
RU2272644C2
(ru)
|
2000-06-29 |
2006-03-27 |
Мерк Патент Гмбх |
Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
|
|
KR100900176B1
(ko)
*
|
2001-03-07 |
2009-06-02 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
|
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
CA2446087C
(en)
*
|
2001-05-03 |
2013-06-18 |
Stephen D. Gillies |
Recombinant tumor specific antibody and use thereof
|
|
BR0214650A
(pt)
*
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
ATE492565T1
(de)
*
|
2002-01-31 |
2011-01-15 |
Randox Lab Ltd |
Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
|
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
|
JP4494977B2
(ja)
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
|
US7935539B2
(en)
*
|
2003-02-14 |
2011-05-03 |
Siemens Healthcare Diagnostics, Inc. |
Generic method for latex agglutination assays
|
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
JP2005172694A
(ja)
*
|
2003-12-12 |
2005-06-30 |
Fuji Photo Film Co Ltd |
タンパク質の検出方法
|
|
DK1699822T3
(da)
*
|
2003-12-30 |
2008-08-04 |
Merck Patent Gmbh |
IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
|
|
WO2005063808A1
(en)
*
|
2003-12-31 |
2005-07-14 |
Merck Patent Gmbh |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
EA011859B9
(ru)
*
|
2004-01-05 |
2013-07-30 |
Емд Лексиген Ресерч Сентер Корп. |
Соединения для адресной доставки препарата к ткани или органу-мишени
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
ATE465176T1
(de)
*
|
2004-12-09 |
2010-05-15 |
Merck Patent Gmbh |
Il-7-varianten mit reduzierter immunogenität
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
CN101505795B
(zh)
|
2006-07-03 |
2013-02-13 |
查尔斯·戴维·阿代尔 |
用于调节细胞粘附分子表达的组合物
|
|
ES2905054T3
(es)
|
2006-11-01 |
2022-04-06 |
Ventana Med Syst Inc |
Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
|
|
US7682789B2
(en)
*
|
2007-05-04 |
2010-03-23 |
Ventana Medical Systems, Inc. |
Method for quantifying biomolecules conjugated to a nanoparticle
|
|
JP2010528285A
(ja)
|
2007-05-23 |
2010-08-19 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
免疫組織化学およびinsituハイブリダーゼーションのためのポリマー担体
|
|
CA2720728C
(en)
|
2008-06-05 |
2018-04-03 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
|
EP2370092A1
(en)
|
2008-12-03 |
2011-10-05 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
|
CA2759333A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
USPP22463P3
(en)
*
|
2010-02-16 |
2012-01-17 |
Menachem Bornstein |
Gypsophila plant named ‘Pearl Blossom’
|
|
WO2012003476A2
(en)
|
2010-07-02 |
2012-01-05 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
CN103282054A
(zh)
|
2011-01-03 |
2013-09-04 |
弗·哈夫曼-拉罗切有限公司 |
抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
|
|
WO2013022599A1
(en)
|
2011-08-05 |
2013-02-14 |
Research Development Foundation |
Improved methods and compositions for modulation of olfml3 mediated angiogenesis
|
|
EP2912064B1
(en)
|
2012-10-24 |
2019-04-24 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
|
WO2015027120A1
(en)
|
2013-08-21 |
2015-02-26 |
Jiang Jean X |
Compositions and methods for targeting connexin hemichannels
|
|
RU2743169C2
(ru)
|
2015-11-06 |
2021-02-15 |
Вентана Медикал Системз, Инк. |
Репрезентативная диагностика
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
CN114470194A
(zh)
|
2015-12-02 |
2022-05-13 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
|
ES2973870T3
(es)
|
2016-03-29 |
2024-06-24 |
Univ Texas |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
|
JP2019528251A
(ja)
|
2016-07-20 |
2019-10-10 |
エスティーキューブ,インコーポレイテッド |
グリコシル化pd−l1に結合する抗体の組合せを使用するがんの処置および治療の方法
|
|
WO2018222689A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
EP3630834A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
CN121609797A
(zh)
|
2017-06-06 |
2026-03-06 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
WO2019055825A1
(en)
|
2017-09-15 |
2019-03-21 |
The Regents Of The University Of California |
INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
|
|
JP2020536855A
(ja)
|
2017-09-26 |
2020-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
がんを治療するための組成物及び方法
|
|
US11691141B2
(en)
|
2017-11-13 |
2023-07-04 |
Roche Sequencing Solutions, Inc. |
Devices for sample analysis using epitachophoresis
|
|
JP7455816B2
(ja)
*
|
2018-09-20 |
2024-03-26 |
ヴェンタナ メディカル システムズ, インク. |
クマリン系架橋試薬
|
|
WO2020074742A1
(en)
|
2018-10-12 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
Detection methods for epitachophoresis workflow automation
|
|
CN110174363A
(zh)
*
|
2019-01-09 |
2019-08-27 |
北京九强生物技术股份有限公司 |
6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
|
|
WO2020229437A1
(en)
|
2019-05-14 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Devices and methods for sample analysis
|
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
CN113736744B
(zh)
*
|
2021-10-14 |
2023-07-18 |
江南大学 |
洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用
|